Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary Background No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system atrophy, rifampicin inhibited formation of α-synuclein fibrils, the neuropathological hallmark of the disease. We aimed to assess the safety and efficacy of rifampicin in patients with multiple system atrophy. Methods In this randomised, double-blind, placebo-controlled trial we recruited participants aged 30–80 years with possible or probable multiple system atrophy from ten US medical centres. Eligible participants were randomly assigned (1:1) via computer-generated permuted block randomisation to rifampicin 300 mg twice daily or matching placebo (50 mg riboflavin capsules), stratified by subtype (parkinsonian vs cerebellar), with a block size of four. The primary outcome was rate of change (slope analysis) from baseline to 12 months in Unified Multiple System Atrophy Rating Scale (UMSARS) I score, analysed in all participants with at least one post-baseline measurement. This study is registered with ClinicalTrials.gov, number NCT01287221. Findings Between April 22, 2011, and April 19, 2012, we randomly assigned 100 participants (50 to rifampicin and 50 to placebo). Four participants in the rifampicin group and five in the placebo group withdrew from study prematurely. Results of the preplanned interim analysis (n=15 in each group) of the primary endpoint showed that futility criteria had been met, and the trial was stopped (the mean rate of change [slope analysis] of UMSARS I score was 0·62 points [SD 0·85] per month in the rifampicin group vs 0·47 points [0·48] per month in the placebo group; futility p=0·032; efficacy p=0·76). At the time of study termination, 49 participants in the rifampicin group and 50 in the placebo group had follow-up data and were included in the final analysis. The primary endpoint was 0·5 points (SD 0·7) per month for rifampicin and 0·5 points (0·5) per month for placebo (difference 0·0, 95% CI –0·24 to 0·24; p=0·82). Three (6%) of 50 participants in the rifampicin group and 12 (24%) of 50 in the placebo group had one or more serious adverse events; none was thought to be related to treatment. Interpretation Our results show that rifampicin does not slow or halt progression of multiple system atrophy. Despite the negative result, the trial does provide information that could be useful in the design of future studies assessing potential disease modifying therapies in patients with multiple system atrophy. Funding National Institutes of Health, Mayo Clinic Center for Translational Science Activities, and Mayo Funds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Self-citationShults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3527-05.2005 · Cited by 254
Cited by
Fanciulli, A., & Wenning, G. K. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1311488 · Cited by 809
Alpha-synuclein biology in Lewy body diseases
Kim, W. S., Kågedal, K., & Halliday, G. M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0073-2 · Cited by 374
Natural history of multiple system atrophy in the USA: a prospective cohort study
Low, P. A., Reich, S. G., Jankovic, J., Shults, C. W., Stern, M. B., Novak, P., Tanner, C. M., Gilman, S., Marshall, F. J., Wooten, F., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00058-7 · Cited by 336
Self-citation(2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.10.004 · Cited by 253
Multiple system atrophy: insights into a rare and debilitating movement disorder
Krismer, F., & Wenning, G. K. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.26 · Cited by 174
Metadata
- Authors
- Low, P. A., Robertson, D., Gilman, S., Kaufmann, H., Singer, W., Biaggioni, I., Freeman, R., Perlman, S., Hauser, R. A., Cheshire, W., Lessig, S., Vernino, S., Mandrekar, J., Dupont, W. D., Chelimsky, T., & Galpern, W. R.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 13
- Issue
- 3
- Pages
- 268-275
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2141041456
- Cited by
- 113
- References
- 2
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(13)70301-6
- The paper
- Low, P. A., Robertson, D., Gilman, S., Kaufmann, H., Singer, W., Biaggioni, I., Freeman, R., Perlman, S., Hauser, R. A., Cheshire, W., Lessig, S., Vernino, S., Mandrekar, J., Dupont, W. D., Chelimsky, T., & Galpern, W. R. (2014). Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(13)70301-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.